Kairos Pharma KAPA
NYSE KAPA
$0.56 -0.02 (-3.12%)
As of: Oct 22, 2026 · 11:37 AM EDT

Kairos Pharma (KAPA) Return on Equity [ROE] (2024 - 2025)

Updated

Kairos Pharma (KAPA) posted Return on Equity [ROE] of -97.99% for FY2025, up 78.28 percentage points from -176.28% in FY2024.

Analysis

Kairos Pharma (KAPA) Return on Equity [ROE] (2024 - 2025) Analysis & Trends

  • Business Quant data shows KAPA's Return on Equity [ROE] at -176.28% in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,170.57 Bn 1,139.16 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 641.68 Bn 560.21 Bn 17.26 Bn 25.32%
3 AbbVie 502.16 Bn 475.27 Bn 12.70 Bn -
4 Merck 375.54 Bn 329.92 Bn 12.21 Bn 7.21%
5 Novartis Ag 302.70 Bn 266.69 Bn 11.24 Bn 31.52%
6 Astrazeneca 268.54 Bn 242.22 Bn 12.86 Bn 21.39%
7 Amgen 242.61 Bn 198.01 Bn 7.24 Bn 83.75%
8 Gilead Sciences 193.36 Bn 167.56 Bn 6.22 Bn -18.38%
9 Pfizer 172.54 Bn 119.18 Bn 10.94 Bn 4.97%
10 Kairos Pharma 10.29 Mn -2.12 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -68.93%
Mar 31, 2025 -56.05%
Dec 31, 2024 -58.66%
Sep 30, 2024 -597.05%
API Access

Kairos Pharma Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=KAPA&period=max&api_key=YOUR_API_KEY